Introduction Glucagon-like peptide-1 receptor agonist(GLP-1RA) is a new type of hypoglycemic drug, the application of which is derived from the incretin effect
This breathing disorder significantly increases the risk of heart failure by 140%, stroke by 60%, and coronary heart disease by 30%
This dose is specifically used to allow your body to acclimatise before the dose is increased
The class of drugs, which include Ozempic and Wegovy, work by mimicking the effects of GLP-1, a type of hormone in the body that impacts everything from the brain to muscle to the pancreas, stomach and liver
Compounded medications from Affinity Whole Health are prepared in FDA-registered compounding facilities and are not FDA-approved drugs
This program changed everything